Panagora Asset Management Inc Novavax Inc Transaction History

Panagora Asset Management Inc

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$36.28 - $75.29 $459,195 - $952,945	-12,657 Closed	0 $0
Q1 2022 May 12, 2022	SELL	$69.73 - $142.9 $733,908 - $1.5 Million	-10,525 Reduced 45.4%	12,657 $932,000
Q4 2021 Feb 10, 2022	SELL	$134.56 - $217.97 $3.5 Million - $5.67 Million	-26,016 Reduced 52.88%	23,182 $3.32 Million
Q3 2021 Nov 10, 2021	BUY	$177.8 - $270.58 $3.14 Million - $4.77 Million	17,639 Added 55.89%	49,198 $10.2 Million
Q2 2021 Aug 11, 2021	SELL	$121.0 - $257.67 $14.8 Million - $31.6 Million	-122,503 Reduced 79.52%	31,559 $6.7 Million
Q1 2021 May 12, 2021	BUY	$112.98 - $319.93 $3.24 Million - $9.18 Million	28,695 Added 22.89%	154,062 $27.9 Million
Q4 2020 Feb 10, 2021	BUY	$78.74 - $139.5 $6.93 Million - $12.3 Million	88,055 Added 236.0%	125,367 $14 Million
Q3 2020 Nov 13, 2020	BUY	$79.44 - $178.51 $2.96 Million - $6.66 Million	37,312 New	37,312 $4.04 Million
Q3 2019 Nov 12, 2019	SELL	$4.02 - $7.84 $156 - $305	-39 Closed	0 $0
Q2 2019 Aug 09, 2019	SELL	$4.93 - $12.2 $15.4 Million - $38 Million	-3,114,527 Reduced 100.0%	39 $0
Q1 2019 May 15, 2019	BUY	$10.2 - $46.8 $31.8 Million - $146 Million	3,114,566 New	3,114,566 $1.72 Million

291

93.4M

6.95M

9.4M

Ticker NVAX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 78,215,104
Market Cap $704M
Description
Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; Nan...

Get notified when there are updates to the investment portfolio of Panagora Asset Management Inc, based on Form 13F filings with the SEC.

Stay updated on Panagora Asset Management Inc with notifications on news.